Vivus Inc $4.24

down -0.04


27/8/2014 01:29 PM  |  NASDAQ : VVUS  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get VVUS Trend Analysis - it has underperformed the S&P 500 by 87%

Partner Headlines

  1. FDA delays Orexigen drug

    IBD
  2. Orexigen Obesity Drug Decision Delayed By FDA

    IBD
  3. Orexigen Shares Plummet Following FDA Decision; Competition Gets A Bump

    Benzinga
  4. Is Vivus About To Get Squeezed?

    Benzinga
  5. Benzinga's Top #PreMarket Gainers

    Benzinga
  6. Shares of Vivus Fall +10% Following Piper Jaffray's Downgrade

    Benzinga
  7. Mid-Day Market Update: US Stocks Fall; Google Shares Rise After Stock Split

    Benzinga
  8. Mid-Morning Market Update: Markets Mostly Flat; Greenbrier Results Beat ...

    Benzinga
  9. Morning Market Losers

    Benzinga
  10. Benzinga's Top #PreMarket Losers

    Benzinga
  11. Benzinga's Top Downgrades

    Benzinga
  12. Biotech Auxilium Boosts Position In Men's Health Care

    IBD
  13. Weekly Three-Year Low Highlight: VVUS, RALY, WILN, COVS

    GuruFocus
  14. Vivus Announces Review Article Summarizing Cardiovascular Benefit-Risk ...

    Benzinga
  15. Auxilium Q4 Beats Estimates, But Guidance Cautious

    IBD
  16. Mid-Afternoon Market Update: Markets Turn Red as Tesla Continues to Rip ...

    Benzinga
  17. Mid-Day Market Update: US Stocks Mostly Flat; Office Depot Shares Decline ...

    Benzinga
  18. Mid-Morning Market Update: Markets Fall; Home Depot Profit Beats Estimates

    Benzinga
  19. UPDATE: Vivus Down Nearly 12% After JP Morgan Downgrade on Lackluster Qsymia ...

    Benzinga
  20. Stocks Hitting 52-Week Lows

    Benzinga
  21. Morning Movers for Feb. 25, 2014: IMUC, MSO, ZU, CARA, VSI, TSLA, XOMA, ...

    Benzinga
  22. Benzinga's Top #PreMarket Losers

    Benzinga
  23. UPDATE: Bank of America Downgrades Vivus as Partnering Prospects Weaken

    Benzinga
  24. US Stock Futures Slip Ahead Of Economic Data

    Benzinga
  25. Benzinga's Top #PreMarket Gainers

    Benzinga
  26. The Top Five Drug Launches Of 2013

    IBD
  27. New ED Drug: Analysis of Vivus’s Prospects

    YCharts
  28. VIVUS Announces License and Commercialization Agreement With Sanofi for ...

    Benzinga
  29. VIVUS Awarded Two US Patents for Qsymia; Patent Coverage for Qsymia Extended ...

    Benzinga
  30. Stocks Hitting 52-Week Lows

    Benzinga
  31. UPDATE: Bank of America Downgrades Vivus on Weaker Partnering Prospects

    Benzinga
  32. Benzinga's Top Downgrades

    Benzinga
  33. US Stock Futures Up Ahead Of Time Warner Earnings

    Benzinga
  34. How Arena’s “$3 Billion” Belviq Withered

    YCharts
  35. UPDATE: Piper Jaffray Downgrades VIVUS Following Management Meetings

    Benzinga
  36. Benzinga's Top Pre-Market Losers

    Benzinga
  37. Vivus, Auxilium up on deal

    IBD
  38. Vivus, Auxilium Gain On Impotence Drug Deal

    IBD
  39. Clinton Group Sends Letter to VIVUS CEO, Says Co. Should Do More to Give ...

    Benzinga
  40. Auxilium Pharmaceuticals Announces License Agreement with Vivus for Marketing ...

    Benzinga
  41. Benzinga's Top Pre-Market Gainers

    Benzinga
  42. Obesity drugs up on report

    IBD
  43. Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and Raises PT

    Benzinga
  44. Obesity Drug Stocks Jump As Cowen Gets Bullish

    IBD
  45. Mid-Day Market Update: Dow Slips Below 15000; CalAmp Jumps On Upbeat Results

    Benzinga
  46. Benzinga's Volume Movers

    Benzinga
  47. Mid-Morning Market Update: Markets Open Lower; Constellation Brands Profit ...

    Benzinga
  48. Benzinga's Top Pre-Market Gainers

    Benzinga
  49. Benzinga's Top Upgrades

    Benzinga
  50. Billionaires Hold Four Stocks, 59% Off

    GuruFocus
Trading Center